PROCTER & GAMBLE HEALTH | VENUS REMEDIES | PROCTER & GAMBLE HEALTH/ VENUS REMEDIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 39.3 | 18.1 | 217.5% | View Chart |
P/BV | x | 16.2 | 0.8 | 1,973.6% | View Chart |
Dividend Yield | % | 5.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH VENUS REMEDIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-24 |
VENUS REMEDIES Mar-24 |
PROCTER & GAMBLE HEALTH/ VENUS REMEDIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,640 | 430 | 1,312.8% | |
Low | Rs | 4,640 | 163 | 2,848.6% | |
Sales per share (Unadj.) | Rs | 693.5 | 449.9 | 154.2% | |
Earnings per share (Unadj.) | Rs | 121.1 | 21.3 | 568.2% | |
Cash flow per share (Unadj.) | Rs | 137.6 | 41.1 | 334.8% | |
Dividends per share (Unadj.) | Rs | 260.00 | 0 | - | |
Avg Dividend yield | % | 5.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 319.1 | 364.7 | 87.5% | |
Shares outstanding (eoy) | m | 16.60 | 13.37 | 124.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.4 | 0.7 | 1,125.6% | |
Avg P/E ratio | x | 42.5 | 13.9 | 305.4% | |
P/CF ratio (eoy) | x | 37.4 | 7.2 | 518.3% | |
Price / Book Value ratio | x | 16.1 | 0.8 | 1,983.2% | |
Dividend payout | % | 214.7 | 0 | - | |
Avg Mkt Cap | Rs m | 85,323 | 3,960 | 2,154.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,152 | 669 | 321.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 11,513 | 6,015 | 191.4% | |
Other income | Rs m | 156 | 116 | 135.0% | |
Total revenues | Rs m | 11,669 | 6,130 | 190.3% | |
Gross profit | Rs m | 2,858 | 596 | 479.5% | |
Depreciation | Rs m | 274 | 264 | 103.6% | |
Interest | Rs m | 7 | 1 | 766.0% | |
Profit before tax | Rs m | 2,733 | 446 | 612.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 723 | 162 | 447.8% | |
Profit after tax | Rs m | 2,010 | 285 | 705.4% | |
Gross profit margin | % | 24.8 | 9.9 | 250.5% | |
Effective tax rate | % | 26.5 | 36.2 | 73.2% | |
Net profit margin | % | 17.5 | 4.7 | 368.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,306 | 3,595 | 258.8% | |
Current liabilities | Rs m | 6,253 | 794 | 787.4% | |
Net working cap to sales | % | 26.5 | 46.6 | 56.9% | |
Current ratio | x | 1.5 | 4.5 | 32.9% | |
Inventory Days | Days | 298 | 28 | 1,049.0% | |
Debtors Days | Days | 271 | 489 | 55.4% | |
Net fixed assets | Rs m | 10,735 | 2,673 | 401.6% | |
Share capital | Rs m | 166 | 134 | 124.2% | |
"Free" reserves | Rs m | 5,131 | 4,742 | 108.2% | |
Net worth | Rs m | 5,297 | 4,876 | 108.6% | |
Long term debt | Rs m | 0 | 387 | 0.0% | |
Total assets | Rs m | 20,041 | 6,268 | 319.7% | |
Interest coverage | x | 380.6 | 475.9 | 80.0% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 0.6 | 1.0 | 59.9% | |
Return on assets | % | 10.1 | 4.6 | 220.7% | |
Return on equity | % | 37.9 | 5.8 | 649.3% | |
Return on capital | % | 51.7 | 8.5 | 608.5% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 69.6 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 8,013 | NA | - | |
Fx inflow | Rs m | 5,421 | 0 | - | |
Fx outflow | Rs m | 8,013 | 0 | - | |
Net fx | Rs m | -2,592 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,283 | 373 | 612.3% | |
From Investments | Rs m | -69 | -72 | 95.3% | |
From Financial Activity | Rs m | -4,181 | -11 | 38,606.6% | |
Net Cashflow | Rs m | -1,967 | 277 | -708.9% |
Indian Promoters | % | 0.0 | 41.8 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 21.5 | 1.2 | 1,817.8% | |
FIIs | % | 6.6 | 1.2 | 560.2% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 58.2 | 82.7% | |
Shareholders | 54,792 | 19,557 | 280.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | VENUS REMEDIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.23% | 2.23% | 0.90% |
1-Month | 3.30% | -8.07% | 1.22% |
1-Year | -0.36% | -23.22% | 46.21% |
3-Year CAGR | 0.84% | -11.84% | 19.63% |
5-Year CAGR | 3.97% | 66.83% | 26.12% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the VENUS REMEDIES share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of VENUS REMEDIES the stake stands at 41.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of VENUS REMEDIES.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 260.0 per share. This amounted to a Dividend Payout ratio of 214.7%.
VENUS REMEDIES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of VENUS REMEDIES.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks experienced a notable rally alongside US equity futures on Monday, marking a positive turn for the markets. The dollar retreated against other currencies as bond yields declined.